In 2014, BIO members reaffirmed and broadened their commitment to responsibly share data from clinical trials with other researchers, including academic and government researchers, in an effort to support additional efforts to improve public health. A JAMA study released yesterday shows that biopharmaceutical companies are keeping that commitment, approving the vast majority of requests for patient-level data from clinical trials. The study looked at three platforms containing clinical trial data from 14 drug companies. Of the 177 requests that had been processed, 87 percent were approved and fewer than 7 percent were rejected.
Subscribe to our e-newsletterVIEW OUR CURRENT ISSUE >
Tagsagriculture healthcare global food crisis BIO EVENT Sustainability BIO Investor Forum Food Plant biotechnology BIOTECH biotechnology health vaccines GMO Answers climate change biotech industry BIO CEO & Investor Conference Greenhouse Gas Emission Patent Reform GMOs Benefits of biotech crops
- Most Popular